Last reviewed · How we verify

NCT03026634: HTx-HDZ-SDB-1

Prevalence and Dynamic of Sleep-disordered Breathing in Patients Pre and Post Heart Transplantation

Completed Last updated 6 May 2021
What this trial tests

trial testing Sleep-disordered breathing in Sleep Disordered Breathing Central in 500 participants. Completed in 31 December 2020.

Timeline
1 January 2017
Primary endpoint
9 October 2020
31 December 2020

Quick facts

Lead sponsorHeart and Diabetes Center North-Rhine Westfalia
StatusCompleted
Study typeOBSERVATIONAL
Enrollment500
Start date1 January 2017
Primary completion9 October 2020
Estimated completion31 December 2020
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

Heart and Diabetes Center North-Rhine Westfalia

Who can join

Adults 18 to 70, any sex, with Sleep Disordered Breathing Central or Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Sleep-disordered breathing is believed to appear at a high prevalence in end-stage heart failure patients and the presence of sleep-disordered breathing has been associated with increased mortality. This study is designed to investigate prevalence and dynamics of sleep-disordered breathing in end-stage heart failure patients pre and post heart transplantation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Nocturnal Hypoxemic Burden Predicts Mortality in Patients Awaiting Heart Transplantation.
    Potratz M, Manukyan T, Schramm R, Costard-Jäckle A, et al · · 2026 · PMID 41306066 · DOI 10.1111/jsr.70256

Verify or expand the search:

Other Heart and Diabetes Center North-Rhine Westfalia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03026634.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing